Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 4
1951 6
1952 23
1953 21
1954 19
1955 16
1956 10
1957 8
1958 8
1959 3
1961 1
1963 1
1964 8
1965 19
1966 22
1967 58
1968 72
1969 94
1970 129
1971 119
1972 159
1973 174
1974 226
1975 158
1976 158
1977 137
1978 115
1979 190
1980 148
1981 144
1982 159
1983 182
1984 213
1985 247
1986 201
1987 174
1988 195
1989 201
1990 230
1991 225
1992 208
1993 295
1994 349
1995 306
1996 284
1997 305
1998 316
1999 281
2000 417
2001 367
2002 362
2003 437
2004 436
2005 509
2006 500
2007 577
2008 644
2009 648
2010 659
2011 770
2012 849
2013 847
2014 837
2015 877
2016 888
2017 946
2018 1097
2019 1093
2020 1055
2021 944
2022 1029
2023 1013
2024 373

Text availability

Article attribute

Article type

Publication date

Search Results

22,042 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Genitourinary System Neoplasm"
Page 1
Application of nanotechnology in the diagnosis and treatment of bladder cancer.
Xu Y, Luo C, Wang J, Chen L, Chen J, Chen T, Zeng Q. Xu Y, et al. J Nanobiotechnology. 2021 Nov 27;19(1):393. doi: 10.1186/s12951-021-01104-y. J Nanobiotechnology. 2021. PMID: 34838048 Free PMC article. Review.
Bladder cancer (BC) is a common malignancy in the genitourinary system and the current theranostic approaches are unsatisfactory. ...
Bladder cancer (BC) is a common malignancy in the genitourinary system and the current theranostic approaches are unsatisfacto …
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Galsky MD, et al. J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555688 Review.
PATIENTS AND METHODS: In this review, the criteria used to define unfit patients are explored and the results of prospective clinical trials evaluating chemotherapeutic regimens in unfit patients are summarized. RESULTS: Several phase II trials and a single, large phase II …
PATIENTS AND METHODS: In this review, the criteria used to define unfit patients are explored and the results of prospective clinical …
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Rodda S, et al. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295. doi: 10.1016/j.ijrobp.2017.01.008. Epub 2017 Jan 6. Int J Radiat Oncol Biol Phys. 2017. PMID: 28433432 Clinical Trial.
PURPOSE: To report the genitourinary (GU) and gastrointestinal (GI) morbidity and erectile dysfunction in a randomized trial comparing 2 methods of dose escalation for high- and intermediate-risk prostate cancer. METHODS AND MATERIALS: ASCENDE-RT (Androgen Su …
PURPOSE: To report the genitourinary (GU) and gastrointestinal (GI) morbidity and erectile dysfunction in a randomized tria …
Approaches to Non-Muscle-Invasive Bladder Cancer.
Slovacek H, Zhuo J, Taylor JM. Slovacek H, et al. Curr Oncol Rep. 2021 Jul 16;23(9):105. doi: 10.1007/s11912-021-01091-1. Curr Oncol Rep. 2021. PMID: 34269918 Review.
Photodynamic Diagnosis-Assisted Transurethral Resection - Lights Out?
Dahm P, Narayan VM. Dahm P, et al. NEJM Evid. 2022 Oct;1(10):EVIDe2200194. doi: 10.1056/EVIDe2200194. Epub 2022 Sep 27. NEJM Evid. 2022. PMID: 38319828
In a randomized trial and accompanying cost-effectiveness analysis, conducted in people with suspected urothelial carcinoma of the bladder, Heer at al.(1) in this issue of NEJM Evidence compare transurethral resection aided by intravesical installation of a photosen …
In a randomized trial and accompanying cost-effectiveness analysis, conducted in people with suspected urothelial carcinoma of …
An Update on Focal Therapy for Prostate Cancer.
Ayerra Perez H, Barba Abad JF, Extramiana Cameno J. Ayerra Perez H, et al. Clin Genitourin Cancer. 2023 Dec;21(6):712.e1-712.e8. doi: 10.1016/j.clgc.2023.04.013. Epub 2023 May 3. Clin Genitourin Cancer. 2023. PMID: 37258359 Review.
The reported incidence of erectile disfunction and urinary incontinence ranges from 3% to 50% and 0% to 34%, respectively. None randomized clinical trial comparing any focal therapy to any radical treatment has been published. ...However, long-term effects an …
The reported incidence of erectile disfunction and urinary incontinence ranges from 3% to 50% and 0% to 34%, respectively. None randomize …
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, Jäderling F, Eklund M, Grönberg H; STHLM3 study group. Nordström T, et al. Lancet Oncol. 2021 Sep;22(9):1240-1249. doi: 10.1016/S1470-2045(21)00348-X. Epub 2021 Aug 13. Lancet Oncol. 2021. PMID: 34391509 Clinical Trial.
We aimed to compare a traditional screening approach with a diagnostic strategy of blood-based risk prediction combined with MRI-targeted biopsies. METHODS: We did a prospective, population-based, randomised, open-label, non-inferiority trial (STHLM3-MRI) in Stockho …
We aimed to compare a traditional screening approach with a diagnostic strategy of blood-based risk prediction combined with MRI-targeted bi …
Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.
Mahal BA, Kwak L, Xie W, Eastham JA, James ND, Sandler HM, Feng FY, Brihoum M, Fizazi K, Sweeney C, Ravi P, D'Amico AV. Mahal BA, et al. JAMA Netw Open. 2023 Nov 1;6(11):e2340787. doi: 10.1001/jamanetworkopen.2023.40787. JAMA Netw Open. 2023. PMID: 37910103 Free PMC article.
DATA SOURCES: PubMed search from 2000 to 2022. STUDY SELECTION: Five prospective randomized clinical trials (RCTs) performed in the US, France, and the United Kingdom evaluating SOC treatment with radiotherapy and androgen deprivation therapy (ADT) or with radical p …
DATA SOURCES: PubMed search from 2000 to 2022. STUDY SELECTION: Five prospective randomized clinical trials (RCTs) performed i …
Genitourinary schistosomiasis.
Al-Ghorab MM, Smith DR. Al-Ghorab MM, et al. Trans Am Assoc Genitourin Surg. 1979;71:70-5. Trans Am Assoc Genitourin Surg. 1979. PMID: 545818
Schistosomiasis is a chronic granulomatous disease endemic in the Middle East and Africa, which undermines the function of the genitourinary tract to a serious degree. It is amenable to medical treatment in the early stages but therapy usually is negated by frequent reinfe …
Schistosomiasis is a chronic granulomatous disease endemic in the Middle East and Africa, which undermines the function of the genitourin …
Emerging role for local therapy in oligometastatic prostate cancer.
Khondakar NR, Owens-Walton J, Daneshvar M, Williams C, O'Connor L, Yerram NK, Pinto PA. Khondakar NR, et al. Clin Adv Hematol Oncol. 2021 Jul;19(7):460-467. Clin Adv Hematol Oncol. 2021. PMID: 34236345 Review.
Evidence from retrospective studies suggests that cytoreductive therapy, including radical prostatectomy, can improve overall survival in these patients. Ongoing randomized trials are comparing cytoreductive therapy with standard-of-care treatment options. Local therapy in …
Evidence from retrospective studies suggests that cytoreductive therapy, including radical prostatectomy, can improve overall survival in th …
22,042 results
You have reached the last available page of results. Please see the User Guide for more information.